iOnctura

Please note: The information displayed on this page might be outdated.
iOnctura: iOnctura is a clinical-stage company applying insights in cancer biology to develop highly selective drugs that can simultaneously inhibit multiple tumor survival mechanisms. iOnctura’s drug development programs combine immune-mediated and direct anti-tumor activity to deliver molecules with superior clinical efficacy and safety in oncology.

Its lead program, IOA-244, has delivered compelling clinical monotherapy efficacy and safety data in solid and hematologic malignancies and has synergistic potential with standard of care agents across tumor types.

iOnctura’s second clinical program, IOA-289, is initiating dosing in a Phase 1b in first-line pancreatic cancer in 3Q22.

iOnctura's strategy is to rapidly demonstrate initial proof-of-concept in orphan indications, allowing for rapid development and potential registration. In parallel, programs are positioned to expand into more highly prevalent indications.

iOnctura has world-class leadership team with deep experience in scaling biotechs to commercialization and is backed by blue chip investors including M Ventures, Inkef Capital, VI Partners, Schroders Capital, and 3B Future Health.
Sector/Industry:
Biotech / Healthcare/Biotechnology
Characteristics:
Based in...
Europe
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Listing
Private
Website:
Address:
Campus Biotech Innovation Park
Avenue Sécheron 15
Genève, 1202
Switzerland

Company Participants at Fall Private Company Showcase 2022

  • Catherine Pickering, CEO

Upcoming Company Event Participation